Skip to main content
Article thumbnail
Location of Repository

The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access

By Laura C Esmail and Jillian Clare Kohler
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). A tragically naive Canadian law for tragically neglected global health.
  2. (1997). After compulsory licensing: coming issues in Canadian pharmaceutical policy and politics. Health Policy
  3. (1993). BD: Agendas and instability in American politics Chicago:
  4. (2003). Canada can carry much more. Toronto: Globe and Mail;
  5. (2003). Canada leading the way. Toronto: The Toronto Star;
  6. (2007). Canada: Report on the statutory review of sections 21.01 to 21.19 of the Patent Act. Ottawa: Government of Canada;
  7. Canada’s Access to Medicines Regime.
  8. Canadian intellectual property: The politics of innovating institutions and interests Toronto:
  9. Canadian-made life saving HIV/AIDS drug heading to Africa under Canada’s Access to Medicines Regime (CAMR).
  10. (2003). Chase S: Ottawa heeds call on AIDS. Toronto: Globe and Mail;
  11. Cite this article as: Esmail and Kohler: The politics behind the implementation of the WTO Paragraph 6 Decision in Canada to increase global drug access.
  12. Commission on Intellectual Property Rights: Public health, innovation and intellectual property rights: Report of the Commission on Intellectual Property Rights, Innovation and Public Health Geneva: World Health Organization;
  13. (2004). Content analysis: An introduction to its methodology Thousand Oaks,
  14. d’Almeida C: Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
  15. (2008). Delivery past due: global precedent set under Canada’s Access to Medicines Regime.
  16. (2007). Esmail LC, Cosio AP: Canada’s implementation of the Paragraph 6 Decision: Is it sustainable public policy? Globalization and Health
  17. (2010). Fixing Access To Medicines Regime Essential.
  18. (1994). Frame reflection: Toward the resolution of intractable policy controversies
  19. Hasenzahl C: Non-voluntary licensing of patented inventions.
  20. (2002). Implications of the Doha Declaration on the TRIPS Agreement and public health Geneva: World Health Organization, Essential Drugs and Medicine Policy;
  21. (1983). International regimes Ithaca:
  22. (2008). JC: Finding Flaws: The Limitations of Compulsory Licensing for Improving Access to Medicines-An International Comparison. Health LJ
  23. (1994). MB: Qualitative data analysis: An expanded sourcebook. 2 edition. Thousand Oaks,
  24. (2007). Médecins sans Frontières: Examples of the importance of India as the “pharmacy for the developing world” Geneva: Médecins sans Frontières;
  25. (2001). Organization: Doha WTO Ministerial 2001: Declaration on the TRIPS agreement and public health,
  26. Organization: Fact sheet: TRIPS and pharmaceutical patents. obligations and exceptions.[ factsheet_pharm02_e.htm].
  27. (2003). Organization: How to develop and implement a national drug policy.
  28. (2004). Organization: The World Medicines Situation. Geneva: World Health Organization;
  29. (1993). Pharmaceuticals, patents, and politics: Canada and Bill C-22.
  30. (2006). Pledges and pitfalls: Canada’s legislation on compulsory licensing of pharmaceuticals for export.
  31. (2002). Policy paradox: The art of political decision making. 2 edition.
  32. (2004). Prakash A: Using ideas strategically: The contest between business and NGO networks in intellectual property rights. International Studies Quarterly
  33. (1988). Promoting elegance in policy theory: Simplifying Lowi’s arenas of power.
  34. (2007). Reflections on pills and poverty. CPJ
  35. (2008). Reich MR: Access: how do good health technologies get to poor people in poor countries Cambridge,
  36. (2008). Right idea, wrong result - Canada’s Access to Medicines Regime.
  37. (2008). Should access to medicines and TRIPS flexibilities be limited to specific diseases?
  38. (2004). Speech from the throne to open the third session of the thirtyseventh Parliament of Canada. Government of Canada;
  39. (2009). Studying public policy: Policy cycles & policy subsystems. 3 edition. Don Mills, Ont:
  40. (2007). The availability and affordability of selected essential medicines for chronic diseases in six low-and middle-income countries. Bulletin of the World Health Organization
  41. (2009). The global politics of pharmaceutical monopoly power. drugs patents, access, innovation and the application of the WTO Doha Declaration on TRIPS and Public Health. Diemen, The Netherlands:
  42. (2005). The Oxford dictionary of philosophy. 2 edition.
  43. (1964). The semisovereign people: a realist’s view of democracy in
  44. (2005). The WTO Medicines Decision: World pharmaceutical trade and the protection of public health.
  45. (2003). Trials and triumphs: The remarkable story of Canada’s generic pharmaceutical industry Canada: Canadian Generic Pharmaceutical Association;
  46. (2003). World Trade Organization: Implementation of Paragraph 6 of the Doha Declaration on the TRIPS Agreement and Public Health:

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.